Gene Therapy for Hemophilia B With Liver-specific Element Mediated by Rep-RBE Site-specific Integration System

Abstract: Adeno-associated virus (AAV) is a nonpathogenic virus capable of targeting human chromosome 19 for integration at AAVS1 site, and a 16 bp Rep binding element (RBE) sequence of AAV was sufficient for mediating this specific integration in the presence of AAV regulation proteins (Rep). Previously, we cotransduced 2 plasmids, pRBE-CMV-hFIX and pRC, into the AAVS1 transgenic mice by hydrodynamic injection, and a long-term expression of human coagulation Factor IX (hFIX) was observed. The corresponding AAVS1 locus site-specific integrations were verified by nested polymerase chain reaction. In this study, we established a novel hFIX expression plasmid, pRBE-HCR-hAAT-hFIX, driven by a liver-specific promoter by replacing the CMV promoter of pRBE-CMV-hFIX with a humanized promoter consisting of HCR-hAAT. The expression of hFIX in vitro was almost the same in transient transfection of pRBE-CMV-hFIX or pRBE-HCR-hAAT-hFIX. AAVS1-specific integrations were identified both in mice transfected with pRC/pRBE-CMV-hFIX cocktail and pRC/pRBE-HCR-hAAT-hFIX cocktail. However, the expression of hFIX of pRBE-HCR-hAAT-hFIX mice was higher and persisted longer. It achieved more than 1% of normal plasma hFIX concentration and maintained for 240 days. The result suggested that RBE-HCR-hAAT element could improve the expression of hFIX and present potential usage of Rep-RBE site-specific integration in gene therapy for hemophilia B.

[1]  Hong-Sung Kim,et al.  Hepatic control elements promote long‐term expression of human coagulation factor IX gene in hydrodynamically transfected mice , 2011, The journal of gene medicine.

[2]  K. High,et al.  Gene therapy for haemophilia: a long and winding road , 2011, Journal of thrombosis and haemostasis : JTH.

[3]  T. VandenDriessche,et al.  Gene therapy strategies for hemophilia: benefits versus risks , 2010, The journal of gene medicine.

[4]  E. Geissler,et al.  High volume naked DNA tail‐vein injection restores liver function in Fah‐knock out mice , 2010, Journal of gastroenterology and hepatology.

[5]  W. Jia,et al.  A 16-bp RBE element mediated Rep-dependent site-specific integration in AAVS1 transgenic mice for expression of hFIX , 2009, Gene Therapy.

[6]  Peter Mayrhofer,et al.  Use of minicircle plasmids for gene therapy. , 2009, Methods in molecular biology.

[7]  M. Sadelain,et al.  Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  K. L. Douglas.  Toward Development of Artificial Viruses for Gene Therapy: A Comparative Evaluation of Viral and Non‐viral Transfection , 2008, Biotechnology progress.

[9]  B. Geest,et al.  Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer , 2008, Gene Therapy.

[10]  W. Jia,et al.  A 16bp Rep binding element is sufficient for mediating Rep-dependent integration into AAVS1. , 2006, Journal of molecular biology.

[11]  Geoffrey Kemball-Cook,et al.  Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. , 2006, Blood.

[12]  T. Flotte,et al.  DNA-dependent PK inhibits adeno-associated virus DNA integration , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Theresa A. Storm,et al.  Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.

[14]  D. Treco,et al.  Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. , 2001, The New England journal of medicine.

[15]  K. Loeb,et al.  Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  I. Peake.  Gene therapy for haemophilia? , 2001 .

[17]  Guisheng Zhang,et al.  Long-term expression of human alpha1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure , 2000, Gene Therapy.

[18]  M. Kay,et al.  Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  J. Wolff,et al.  High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. , 1999, Human gene therapy.

[20]  Dexi Liu,et al.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA , 1999, Gene Therapy.

[21]  R. Kotin,et al.  Determination of adeno-associated virus Rep68 and Rep78 binding sites by random sequence oligonucleotide selection , 1995, Journal of virology.

[22]  M. W. Flye,et al.  Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. , 1994, Blood.

[23]  M. Kay,et al.  In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. , 1993, Science.

[24]  R. Kotin,et al.  Characterization of a preferred site on human chromosome 19q for integration of adeno‐associated virus DNA by non‐homologous recombination. , 1992, The EMBO journal.

[25]  P. Leder,et al.  The cytomegalovirus enhancer: a pan-active control element in transgenic mice , 1990, Molecular and cellular biology.